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Indolent natural killer (NK) cell lymphoproliferative
disorders include a heterogeneous group of patients
in whom persistent expansions of mature, typically
CD56, NK cells in the absence of any clonal marker
are present in the peripheral blood. In the present
study we report on the clinical, hematological, immu-
nophenotypic, serological, and molecular features of
a series of 26 patients with chronic large granular NK
cell lymphocytosis, whose NK cells were either CD56
or expressed very low levels of CD56 (CD56/dim NK
cells), in the context of an aberrant activation-related
mature phenotype and proved to be monoclonal using
the human androgen receptor gene polymerase chain
reaction-based assay. As normal CD56 NK cells,
CD56/dim NK cells were granzyme B, CD3, TCR/
, CD5, CD28, CD11abright, CD45RAbright,
CD122, and CD25 and they showed variable and het-
erogeneous expression of both CD8 and CD57. Never-
theless, they displayed several unusual immunopheno-
typic features. Accordingly, besides being CD56/dim,
they were CD11b/dim (heterogeneous), CD7/dim
(heterogeneous), CD2 (homogeneous), CD11cbright
(homogeneous), and CD38/dim (heterogeneous).
Moreover, CD56/dim NK cells heterogeneously ex-
pressed HLA-DR. In that concerning the expression of
killer receptors, CD56/dim NK cells showed bright
and homogeneous CD94 expression, and dim and het-
erogeneous reactivity for CD161, whereas CD158a and
NKB1 expression was variable. From the functional
point of view, CD56/dim showed a typical Th1 pattern
of cytokine production (interferon-, tumor necro-
sis factor-). From the clinical point of view, these
patients usually had an indolent clinical course, pro-
gression into a massive lymphocytosis with lung in-
filtration leading to death being observed in only one
case. Despite this, they frequently had associated cy-
topenias as well as neoplastic diseases and/or viral
infections. In summary, we describe a unique and
homogeneous group of monoclonal chronic large
granular NK cell lymphocytosis with an aberrant ac-
tivation-related CD56/dim/CD11b/dim phenotype
and an indolent clinical course, whose main clinical
features are related to concomitant diseases. (Am J
Pathol 2004, 165:1117–1127)
Indolent natural killer (NK) cell lymphoproliferative disor-
ders (LPDs) are usually designated as chronic NK cell
lymphocytosis (CNKCL) or chronic NK-large granular
lymphocytes (LGL) LPD.1–6 CNKCLs are heterogeneous
and they most probably include reactive chronic NK cell
lymphocytosis, true chronic NK cell large granular lym-
phocyte (LGL) leukemia, and even some aggressive NK
cell lymphoma/leukemia cases,7–9 because of difficulties in
establishing the clonal nature of the NK cell proliferation.
Previous studies have shown that in most CNKCL
cases the expanded population of NK cells co-expresses
CD56, CD16, and CD94 and displays NK activity. Such
phenotypic and functional features are similar to those
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observed in neoplastic NK cells from aggressive NK cell
leukemia/lymphoma, nasal, and nasal-type lympho-
mas.10 Despite this, few cases of CNKCL and LGL leu-
kemias of CD56/dim NK cells have been sporadically
described10–13 or used to establish NK cell lines.14 NK
cells showing decreased or no expression of CD56 have
not been reported either in healthy individuals or in dis-
ease conditions associated to either a transient or per-
sistent increase in the number of NK cells in the periph-
eral blood (PB);15 in such cases, the expanded cell
population constantly shows co-expression of CD16 and
CD56 frequently in association with acute or chronic
NK cell activation features. These findings may sug-
gest that a CD56/dim NK cell phenotype could be
aberrant and reflect underlying clonal genetic abnor-
malities. However, to the best of our knowledge no
study has been reported so far in which this unique
group of CNKCL is studied in detail.
In contrast to both CD8/TCR and CD4/TCR
T-cell LGL leukemias, in which the most characteristic
clinical manifestations of the disease—such as its asso-
ciation with cytopenias and arthritis or second neopla-
sias—are well known,16–18 the clinical features associ-
ated with CNKCL including NK cell LGL leukemia, are far
away from being well established. Previous studies have
suggested a possible association of CNKCL with cytope-
nias, vasculitis, neutropenic or nonneutropenic fever, BM
granulomas,1–3,19,20 and even Epstein-Barr virus (EBV)
infection in endemic areas.21,22
In the present study we report on the clinical, hemato-
logical, immunophenotypical, functional, serological, and
molecular features of 26 patients with CNKCL in whom
the expanded PB NK cells were either CD56 or ex-
pressed very low levels of surface CD56 (CD56/dim
CNKCL) in the context of an aberrant immunophenotype
and a mature LGL morphological appearance.
Materials and Methods
Patients
A total of 26 consecutive patients with CNKCL whose
LGL appearing circulating NK cells were CD56/dim,
were studied at diagnosis in two different centers. These
centers received cases referred for the diagnosis of T/NK
chronic LPD from other hospitals in Portugal (Cytometry
Unit of the Hematology Service at the Hospital Geral de
Santo Anto´nio, Porto, Portugal) and in Spain (Cytometry
Service, University and University Hospital of Salamanca,
Salamanca, Spain). Altogether, these CD56/dim patients
represented 20% of the total group of 130 CNKCL cases
and 1% of a total of 2368 mature chronic LPDs diagnosed
in both institutions between September 1997 and Decem-
ber 2002, from which 64% were B-cell chronic lympho-
cytic leukemias. Results obtained were compared to
those observed on PB CD56 NK cells from 12 age- and
sex-matched healthy individuals, 15 patients with acute
viral infection, and 15 patients with CD56 chronic NK
cell lymphocytosis associated with tumors or chronic in-
fections whose immunophenotypic features have been
previously published in detail.15,23
Immunophenotypic Studies
In all cases cell surface immunophenotypic studies were
performed as previously described in detail.10 Stainings
were performed using an ethylenediaminetetraacetic ac-
id-anti-coagulated whole blood stain-lyse-and-then-wash
method and a four-color panel of monoclonal antibodies
conjugated with fluorescein isothiocyanate, phyco-
erythrin, phycoerythrin-cyanine 5, or peridin chlorophyll
protein and allophycocyanine directed against the follow-
ing antigens: TCR, TCR, CD8, CD4, CD3, CD28,
CD2, CD7, CD56, CD5, CD57, CD11c, CD38, CD11b,
CD45RA, CD45RO, CD122, CD25, CD11a, HLA-DR,
CD158a, CD161, CD16, NKB1, and CD94.23 In addition,
the expression of cytoplasmic granzyme B was evaluated
using the Fix and Perm reagent kit (Caltag Laboratories,
Burlingame, CA), according to the manufacturer’s in-
structions.
Functional analysis of cytokine production by the ex-
panded NK cells was also performed as previously de-
scribed.18 Briefly, 500 l of heparinized blood were
placed into a tube containing 500 l of RPMI 1640 culture
medium (BioWhittaker, Walkersville, MD) supplemented
with 2 mol/L of L-glutamine. Cells were cultured for 4
hours at 37°C in a 5% CO2 and 95% humidity sterile
environment in the presence of 25 ng/ml of phorbol-12
myristate 13-acetate, 1 g/ml of ionomycin, and 10 g/ml
of brefeldin A (stimulated samples) or only brefeldin A
(nonstimulated samples). Once this incubation period
was completed, each sample was sequentially stained
for the CD3 and CD19 surface antigens—and intracellu-
lar cytokines—interleukin (IL)-2, IL-4, IL-10, IL-13, inter-
feron (IFN)-, tumor necrosis factor (TNF)-, and TNF-
.18 In these studies NK cells were identified as CD19,
CD3 lymphocytes.
Data acquisition was performed in each of the two
centers in FACSCalibur flow cytometers [Becton/Dickin-
son Biosciences (BDB), San Jose, CA], equipped with
two lasers using the Cell QUEST software program
(BDB). Information on a minimum of 2  105 events was
acquired and stored as list mode data for each staining.
For data analysis the Paint-A-Gate PRO software pro-
gram (BDB) was used. Identification and enumeration of
NK cells present in the sample was performed as follows:
the percentage of NK cells from all PB nucleated cells
and lymphocytes was calculated by selecting CD3 lym-
phoid cells that expressed CD2 and/or CD7; then, the
normal and abnormal NK cell populations were identified
according to the unique pattern of expression of the
CD56, CD2, and CD7 antigens observed in normal NK
cells15,23 and the proportion of abnormal CD56/dim,
normal CD56, and normal CD56 NK cells within total
NK cells was determined. Afterward, the abnormal CD56/
dim NK cell population was characterized for the expres-
sion of the other cell surface antigens analyzed. For each
antigen studied, the following characteristics were record-
ed: 1) percentage of positive cells; 2) intensity of expres-
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sion— absent (), low (/), moderate (), high (),
very high ()—evaluated as their mean fluorescence
intensity (MFI) (arbitrary relative linear units scaled from 0
to 10,000 fluorescence channels) and; 3) pattern of anti-
gen expression (homogeneous versus heterogeneous),
evaluated by the coefficient of variation (CV).
Flow Cytometry DNA Cell Content Studies
DNA studies were performed in a subset of patients (n 
6). Briefly, PB cells were double stained for either surface
CD16 or CD94 and nuclear DNA (DNA-Prep; Beckman-
Coulter, Hialeah, FL) and acquired in an EPICS-XL-MCL
flow cytometer using the XL2 software (Beckman-Coulter).
Both the DNA ploidy status and the cell cycle distribution
of PB NK cells were evaluated using the MultiCycle soft-
ware (Phoenix Flow Systems, San Diego, CA).
Human Androgen Receptor Gene
Assay (HUMARA)
To confirm the clonal origin of the aberrant NK cell pop-
ulations, the pattern of inactivation of chromosome X was
studied in 4 of 15 female patients by assessing the meth-
ylation of human androgen receptor gene using the HU-
MARA polymerase chain reaction (PCR)-based assay.24
For that purpose, purified CD56/dim NK cells (mean,
97  2.6%; range, 93.6 to 99.6%) and the corresponding
NK cell-depleted leukocyte fractions from the four female
patients were studied in parallel. NK cells were purified
by a single immunomagnetic depletion step using the
Human NK Cell Isolation Kit II in the automated magnetic
cell separator autoMACS (Miltenyi Biotec, Bergisch Glad-
bach, Germany), strictly following the manufacturer’s rec-
ommendations. Digestion of genomic DNA with the meth-
ylation-sensitive restriction endonuclease HapII and
subsequent PCR amplification of the methylated (inacti-
vated) alleles was performed, as previously described.24
Molecular Analysis of TCR Gene
Rearrangements
Molecular analyses of TCR gene rearrangements were
performed in most cases using either conventional South-
ern blot-based TCR- gene (n  2) or PCR-based TCR-
gene (n  12) techniques or both (n  6). Briefly, DNA
was extracted from mononuclear cells obtained by den-
sity gradient centrifugation, using the chloroform method.
For Southern blot, DNA was digested with the EcoRI and
HindIII restriction enzymes and DNA fragments were sep-
arated by a 0.8% agarose gel electrophoresis and trans-
ferred to nitrocellulose membranes by vacuum blotting,
UV fixed, and hybridized with 32P-labeled probes for the
TCR- gene region (C, TCRBC, and TCRBJ2; DAKO
A/S, Glostrup, Denmark). PCR amplification of the TCR-
gene was done using the BIOMED-2 primer sequences
and protocols,25 with a limit of detection varying from 1 to
10%, depending on the polyclonal TCR repertoire com-
plexity, and the type of TCR- gene rearrangements.26
Serological and Molecular Studies for Viral
Infection
Sera from nine patients were tested for the presence of
IgM and IgG antibodies against cytomegalovirus (CMV),
EBV viral capside (EBV-VCA), and nuclear (EBNA) anti-
gens, parvovirus, herpes simplex (HSV) type 1 and 2,
varicella zoster (VZV), rubella, and hepatitis A, B, and C
viruses. In addition, 13 patients were tested for the pres-
ence of antibodies against human immunodeficiency
(HIV) and human T-cell leukemia/lymphoma (HTLV) type
I and type II viruses.
The presence of HTLV-1, CMV, EBV, HSV, VZV, and
human herpesvirus type 6 (HHV-6) DNA sequences was
also evaluated in nine patients by real-time PCR assays
using DNA extracted from PB mononuclear cells with the
MagNA Pure machine and the MagNA Pure LC total
nucleic acid isolation kit (Roche Diagnostics, Mannheim,
Germany). Amplification of CMV, HSV, and HHV-6 DNA
was done using an in-house developed real-time PCR
assay with synthetic genetic primers and probes (Epoch,
USA) in the SmartCycler system (Cepheid, USA) whereas
EBV and VZV DNA were detected using commercially
available kits (Artus, Hamburg, Germany) and the Light-
Cycler System (Roche Diagnostics). HTLV-1 DNA was
detected using an in-house developed real-time PCR
assay with previously described primers and probes27
and the LightCycler FastStart DNA Master Hybridization
Probes (Roche Diagnostics).
Other Laboratory Parameters
Other laboratory parameters included a full hematologi-
cal blood cell count, a morphological evaluation of blood
smears, and a routine biochemical survey including se-
rum levels of liver enzymes, creatinine, lactate dehydro-
genase, 2-microglobulin, immunoglobulins (Igs), anti-
nuclear antibodies, and rheumatoid factor.
Statistical Analyses
For all variables under study, median, mean, SD, and
range values were calculated. To explore for the statisti-
cal significance of the differences observed between
groups the Mann-Whitney U-test was used (SPSS software,
version 11; SPSS, Chicago, IL). P values 0.05 were con-
sidered to be associated with statistical significance.
Results
Clinical and Laboratory Findings
Table 1 summarizes the clinical and hematological find-
ings at diagnosis for the 26 patients studied. As may be
seen in Table 1, all patients were adults more than 35
years of age and there was a slight predominance in
females (male/female ratio of 0.73). In the great majority
of the cases (18 of 26) lymphocytosis was an occasional
finding in either a routine blood analysis (n  9) or in
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blood analysis performed during investigation or monitor-
ing of another pathological condition (n  9), consisting
of diabetes mellitus (n 1), arthritis (n 1), adenomega-
lies (n  1), idiopathic thrombocytopenic purpura (n 
3), autoimmune hemolytic anemia (n  1), and B-cell
lymphoma (n  2). In the remaining eight cases, diagno-
sis was obtained in blood analyses performed because
of co-existing active pathological conditions: HIV infec-
tion (n  3), prostatic carcinoma (n  1), colon carci-
noma, refractory anemia with excess of blasts, autoim-
mune hemolytic anemia (n 1), hepatitis C virus infection
(n  1), idiopathic thrombocytopenic purpura (n  1),
and breast carcinoma (n  1).
At the moment of diagnosis 96% of the patients had
lymphocytosis (5.0  109/L). Hemoglobin, neutrophil,
and platelet counts were decreased in 46%, 44%, and
28% of the cases, respectively. Symptomatic anemia
(75 g/L) requiring red blood cell transfusion was ob-
served in only three patients who suffered from severe
Coomb’s-negative (n  2) or Coomb’s-positive (n  1)
hemolytic anemia; in addition, one patient had a past
history of autoimmune hemolytic anemia that responded
completely to corticosteroids plus splenectomy and an-
other patient had a past episode of hemolytic anemia of
unknown origin that solved spontaneously. Neutropenia
was severe (500  106/L) in six cases, although only
one patient had a past history of repeated or severe
infections. Clinically relevant thrombocytopenia (50 
109/L) was observed at diagnosis of CNKCL in only two
cases, one of them being diagnosed has idiopathic
thrombocytopenic purpura; in addition, three other pa-
tients had a past history of idiopathic thrombocytopenic
purpura. One of these cases had a partial response to
corticosteroids and a complete response to splenec-
tomy; the other two cases had been successfully treated
with corticosteroids. Four patients underwent splenec-
tomy 2 to 12 years before the diagnosis of CNKCL, either
for an associated condition (n  3) or because of trauma
(n  1).
At diagnosis, all except three patients were asymptom-
atic. In these three cases symptoms were related to
cytopenias and/or an associated-disease. Physical ex-
amination (Table 1) showed the presence of splenomeg-
aly, adenomegalies, and hepatomegaly in only a minor
proportion of cases (15%). Only one patient suffered from
arthritis, which was diagnosed as rheumatoid arthritis. Skin
lesions were not found neither were fever or vasculitis.
Increased lactate dehydrogenase (mean  SD, 484 
185 U/L; range, 208 to 856 U/L) and 2-microglobulin
(mean  SD, 3.24  1.61; range, 1.30 to 7.10) serum
levels were observed in 50% and 80% of the cases,
respectively. Ig serum levels were abnormal in 15 of 21
patients and consisted of increased IgM (n 3), IgG (n
7), IgA (n  5), and/or IgE (n  2); in addition, 5 patients
had moderate IgA (n 4) or IgG (n 1) hypogammaglobu-
linemia. Serum rheumatoid factor was positive and serum
levels of anti-nuclear antibodies were increased in 4 of 9
and 3 of 11 patients tested, respectively.
Studies aimed at detecting underlying viral infections
confirmed the presence of HIV infection in three patients,
being associated with HTLV1 infection in one of them.
Hepatitis C virus infection was detected in three addi-
tional patients. Moreover, serological studies suggested
past infection with CMV, EBV, and HSV-1 each in nine of
nine cases tested, HSV-2 in three of seven cases, VZV in
seven of eight patients studied, parvovirus in five of nine,
and hepatitis B virus in two of nine cases tested. Sero-
logical data from a control group of 5853 outcare adult
patients showed a high incidence of previous infection
with the viruses analyzed here (CMV, 80%; EBV/anti-
VCA, 88%; EBV/anti-EBNA, 80%; HSV, 88%; VZV, 85%;
and parvovirus, 77%).
Immunophenotypic Features of CD56/dim
NK Cells
NK cells accounted for 68  18% of all PB lymphocytes
(range, 19 to 95%) increased PB NK cell counts being
observed in all cases. The vast majority (97.6  4.1%) of
all PB NK cells had an abnormal immunophenotype as
illustrated in Figure 1 and the main phenotypic differ-
ences and similarities between CD56/dim NK cells,
normal, and activated CD56 NK cells are detailed in
Figure 2 and illustrated in Figure 3. As shown there, the
most relevant immunophenotypic feature consisted on an
abnormally low (P  0.0001) CD56 expression on the
majority of PB NK cells (CD56/dim NK cells); most of
the CD56/dim NK cells (78  21%) were CD56 and a
minority of them (22  21%) showed dim and heteroge-
neous CD56 expression, as compared to normal NK
cells. Residual CD56 and CD56 NK cells were de-
tected in all but one patient, accounting for only 2.3 
4.1% and 0.3  0.3% of total PB NK cells, respectively.
Table 1. Clinical and Laboratory Characteristics of Individuals
with Chronic CD56/dim NK Cell LGL
Lymphocytosis
Age 68  17 (37–94)
Sex (male/female) 11/15 (42%/58%)
Reason for consulting
Routine blood analysis (65%)
Adenomegalies (4%)
Viral infection (15%)
Concomitant malignant neoplasias (12%)
Other (ITP) (4%)
Physical examination
Adenophaties (13%)
Splenomegaly (15%)*
Hepatomegaly (4%)
Skin lesion (0%)†
Arthritis (4%)
Peripheral blood cell counts
Hemoglobin (g/L) 123  27 (66–163)
Platelets (109/L) 186  83 (26–417)
WBC (109/L) 128  96 (2–43)
Neutrophils (109/L) 2.3  2.4 (0.1–11.4)
Lymphocytes (109/L) 9.0  8.9 (1.2–40.8)
NK cells (109/L) 6.7  8.4 (0.5–38.7)
CD56/dim NK-cells (109/L) 6.6  8.3 (0.5–38.7)
* Four cases had splenectomy before diagnosis of CNKCL for an
associated condition corresponding to an idiopathic thrombocytopenia
purpura (n  1), autoimmune hemolytic anemia (n  1), trauma (n 
1), or splenic B-cell lymphoma (n  1).
† Two of the patients had past history of herpetic skin lesions, infection
with HZV being confirmed with serological analysis in one of them.
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As normal CD56 cells, CD56/dim NK cells were
granzyme B, CD3/TCR, and CD5 and displayed a
variable and heterogeneous reactivity for CD8 except in
three patients who had abnormally high and homoge-
neous CD8 expression. Besides showing defective CD56
expression, the expanded NK cells also had abnormally
low expression of CD7 (P  0.0001), CD38 (P  0.0002),
and other surface molecules involved in NK cell adhesion
and cytotoxic activity, such as CD11b (P 0.0001, CD11b
(P  0.0001), CD57 (P  0.008), and CD16 (P  0.05)
(Figure 2). In contrast, abnormal CD56/dim NK cells had
a stronger and more homogeneous (ho) CD2 (P  0.0001)
and CD11c expression (P  0.0005) (Figure 2).
In that concerning the expression of killer receptors,
most CD56/dim NK cells were CD94 with a higher
(P  0.03) and more homogeneous (P  0.02) expres-
sion than that observed in normal CD56 NK cells.
CD161 and CD158a were dimly and heterogeneously
expressed in a variable fraction of CD56/dim NK cells
whereas NKB1 expression was found in a variable pro-
portion (49 34%) of CD56/dim NK cells in only 29% of
the patients.
As normal PB NK cells, CD56/dim NK cells were
CD25, CD5, CD11abright, ho CD45RAbright, ho, and
CD122. Nevertheless, CD56/dim NK cells expressed
much higher levels of HLA-DR (P  0.0001) than normal
CD56 NK cells, the majority of CD56/dim NK cells
being HLA-DR (mean of 62  23%, versus 16  14%
observed on normal CD56 NK cells; P  0.0001). In
addition, CD122 and CD45RA expression were weaker
(P  0.0001 and P  0.0009, respectively) and more
heterogeneous (P  0.01 and P  0.03, respectively)
whereas reactivity for CD45RO was slightly higher (P 
0.03) in the aberrant CD56/dim NK cells as compared
to normal PB NK cells.
Some of the immunophenotypic differences found be-
tween normal and CD56/dim NK cells—ie, overexpres-
sion of CD11c and HLA-DR and down-regulation of
CD45RA accompanied in some cases by co-expression
of CD45RO in a variable fraction of NK cells—do in fact
reproduce the immunophenotypic changes that typically
occur on recently activated CD56 NK cells, whereas
other—ie, increased CD2 expression and decreased and
heterogeneous expression of CD7, CD11b, and CD38—
were similar to those typically observed in conditions of
chronic NK cell stimulation.15 Despite these similarities
between CD56/dim NK cells and either recently or
chronically activated CD56 NK cells, major differences
were observed in the pattern of expression of the above-
mentioned markers. Accordingly, CD56/dim NK cells
Figure 1. Illustrative bivariate histograms of the most characteristic immunophenotypic features of abnormally expanded CD56/dim NK cells (red dots) in a
patient with CNKCL. Black and gray dots correspond to the T and B cells present in the same blood sample, respectively.
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had higher and more homogenous (P  0.002) expres-
sion of CD11c, greater percentages of CD57 cells (P 
0.007), and lower levels of HLA-DR (P  0.0006) as
compared to recently activated NK cells. Additionally,
CD2 expression was more homogeneous (P  0.004),
down-regulation of CD7 and CD11b were more pro-
nounced (P  0.0001), and CD7 expression was even
more heterogeneous (P  0.02) on CD56/dim NK cells
than on chronically activated CD56 NK cells. Moreover,
disagreement between down-regulation of CD11b and
CD38 expression, consisting of a CD11b/CD38 phe-
notype, was frequently found in CD56/dim NK cells (10
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of 26 cases) but not on chronically activated CD56 NK
cells.
Cytokine Production by CD56/dim NK Cells
As normal PB NK cells, CD56/dim NK cells showed a
typical Th1 pattern of cytokine production after stimula-
tion with phorbol-12 myristate 13-acetate plus ionomycin
(Figure 4). Accordingly, these cells produced IFN- and
TNF-, at the same time they failed to secrete IL-2, IL-4,
IL-10, IL-13, and TNF- under these stimulatory condi-
tions. A more detail comparison with normal PB NK cells
showed that the proportion of CD56/dim NK cells pro-
ducing both IFN- and TNF- and the amount of these
cytokines produced per cell was similar to that of normal
CD56 PB NK cells (75  31% versus 75  21%, P  0.7,
and 52%  36% versus 36  12%, P  0.5, respectively).
Flow Cytometry DNA Cell Contents of
CD56/dim NK Cells
In all cases analyzed, CD56/dim NK cells had a diploid
DNA content and a very low fraction of cells in the S
(0.4  0.5%) and G2/M (0.3  0.4%) cell cycle phases.
Figure 2. Immunophenotypic characteristics of PB NK cells from patients with CD56/dim CNKCL (red boxes, n 26) as compared to healthy individuals (gray
boxes, n  12), patients with acute viral infection (green boxes, n  15), and patients with CD56 CNKCL associated with chronic viral infection or neoplasias
(blue boxes, n  15). The notched box and whiskers show nonparametric statistics, including the median, the lower and upper quartiles, and the 95%
confidence interval around the median (notched box); the dotted lines connect the nearest observations within 1.5 interquartile ranges of the lower and upper
quartiles; red crosses or circles indicate outliers. Differences between the groups were explored using the Mann-Whitney U-test. Statistically significant P values
(0.05): 1) CD56/dim CNKCL versus healthy individuals: CD2(CV): 0.0001; CD7(MFI): 0.0001; CD7(CV): 0.0001; CD8(MFI): 0.04; CD11a(CV): 0.006;
CD11b (MFI):  0.0001; CD11c (MFI): 0.002; CD11c(CV): 0.0005; CD16 (MFI): 0.04; CD38 (MFI): 0.0002; CD38(CV): 0.003; CD45RA (MFI): 0.0009; CD45RA(CV):
0.03; CD45RO (MFI): 0.03; CD56 (MFI): 0.0001; CD56(CV): 0.0001; CD57 (MFI): 0.008; CD94(CV): 0.02; CD122(MFI): 0.0001; CD122(CV): 0.01; HLA-DR
(MFI): 0.0001; HLA-DR(CV): 0.05.2) CD56/dim CNKCL versus acute viral infection: CD2(CV):  0.0001; CD7(MFI): 0.0001; CD7(CV); 0.0001; CD11a(CV):
0.002; CD11b (MFI): 0.0005; CD11c(CV): 0.002; CD16(CV): 0.005; CD38 (MFI): 0.0001; CD38(CV): 0.0002; CD45RA(CV): 0.02; CD45RO (MFI): 0.0007; CD56
(MFI): 0.0001; CD56(CV):0.0001; CD57(CV): 0.02; CD122(MFI): 0.02; CD122(CV): 0.009; HLA-DR (MFI): 0.0006.3) CD56/dim CNKCL versus CD56 CNKCL
associated to neoplasias or chronic viral infections: CD2(CV): 0.004; CD7(MFI): 0.0001; CD7(CV); 0.02; CD11b (MFI): 0.0001; CD11c (MFI): 0.0003;
CD11c(CV): 0.0001; CD38(CV): 0.002; CD45RA (MFI): 0.03; CD56 (MFI): 0.0001; CD56(CV):0.0001; CD57 (MFI): 0.0003; CD57(CV): 0.003; CD94(CV): 0.01;
CD161(CV): 0.0002; HLA-DR (MFI):  0.0001.
Figure 3. Representative bivariate dot plots illustrating the most relevant
phenotypic differences between PB NK cells (red dots) from a healthy
individual (column A), and patients with acute (column B) and chronic
(column C) viral infections as well as a case of CD56/dim CNKCL (col-
umn D).
Figure 4. In vitro TNF- and IFN- production by phorbol-12 myristate
13-acetate plus ionomycin-stimulated NK cells from CD56/dim CNKCL
patients (filled boxes) and healthy individuals (open boxes). Results are
expressed as percentage of cytokine NK cells (A) and mean fluorescence
intensity levels of expression of cytoplasmic cytokines in NK cells (B). Boxes
extend from the 25th to the 75th percentiles; the line in the middle and the
vertical lines represent median values and 95% confidence intervals, re-
spectively. No significant differences (P  0.05) were observed between the
median values of the patient and the control groups using the Mann-Whitney
U-test.
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Clonality of CD56/dim NK Cells
Phenotipically aberrant CD56/dim NK cell from four female
patients studied showed a monoclonal pattern of chromo-
some X inactivation with a single HUMARA gene allele; in
contrast, the NK-depleted leukocyte fractions from the
same female patients, used as polyclonal controls, showed
an heterozygous genotype for the HUMARA gene, with a
random pattern of chromosome X inactivation.
TCR Gene Rearrangement Molecular Studies
Presence of (mono)clonal TCR- and/or gamma gene
rearrangements was found in three cases (none of them
corresponding to patients whose CD56/dim NK cells
were proven to be monoclonal by HUMARA PCR-based
assays). A detailed analysis of PB T cells, including the
study of the repertoire of the TCR- chain variable re-
gions (TCR-V),28 revealed T-cell abnormalities compat-
ible with a clonal T-cell proliferation in one of these three
CD56/dim CNKCL cases. This patient had a phenotyp-
ically abnormal CD8/CD56 TCR-V-restricted T-cell
population, representing 36% of CD8/TCR PB T
cells (2% of lymphocytes). No phenotypically aberrant
T-cell populations showing a TCR-V pattern suggestive
of T-cell (mono)clonality were detected in the other two
cases.
Follow-Up and Clinical Outcome
At the moment of closing the study, median follow-up was
12 months (range, 1 to 63 months) and all patients re-
mained alive except four patients who died because of
disease progression (n  1) or an associated malignant
neoplasia (n  3).
Lymphocyte counts remained stable during follow-up
in all but three cases: one patient showed a progressive
increase in PB lymphocyte counts from 4.1  109/L up to
80.0  109/L throughout a 58-month follow-up period,
associated with lung infiltration and death; in another
patient lymphocyte counts decreased from 5.4  109/L
toward normal values after an episode of septicemia,
although the abnormal NK cell population still persisted in
blood, increasing again afterward up to 20.0  109/L;
and a third patient experienced spontaneous complete
remission. At the moment of closing this study none but
one of the patients required specific cytotoxic treatment
because of CNKCL.
During follow-up, recurrent/severe infections occurred
in six cases, four of whom corresponded to patients with
severe neutropenia. Overall, seven patients had a past or
present history of hematological (n  3) or nonhematologi-
cal (n  3) tumors, or developed nonhematological tumors
during follow-up (n  2). Hematological malignancies cor-
responded to B-cell lymphomas (n 2) and to a myelodys-
plastic syndrome (n  1). Nonhematological tumors corre-
sponded to prostatic, bladder, colon, breast, and skin
carcinomas (one case each). Three of these seven cases
died because of the evolution of the neoplastic disease.
Discussion
LGL leukemia has been recognized as a distinct entity in
the Revised European American29 and World Health Or-
ganization30 classifications and a number of NK cell-
derived cases have been included in LGL-leukemia se-
ries.16 Nevertheless, assessment of NK cell clonality still
remains a challenge and no definitive consensus exists
on the criteria to establish the diagnosis of NK cell leu-
kemia. Indeed, although in T-cell disorders clonality can
be detected through molecular analyses of TCR genes,
molecular markers for the assessment of the clonal na-
ture of NK cells such as X-linked DNA analysis and clonal
integration of viral DNA in the genome of the infected
cell31,32 are frequently not applicable or available in most
laboratories. Moreover, cytogenetic studies are of limited
utility because recurrent chromosomal abnormalities
have not been described in patients with CNKCL.
Recent studies show that neoplastic cells from almost
every chronic and acute leukemia display phenotypic
aberrations that can be used for the reliable identification
of neoplastic cells.33 Although no similar phenotypic
study has been performed in CNKCL and NK cell leuke-
mia/lymphoma, we have recently established the bases
to define aberrant immunophenotypes in CNKCL through
a detailed analysis of the immunophenotypes of CD56
and CD56 PB NK cells in normal individuals23 and the
phenotypic changes that occur in vivo in early and late
phases of NK cell activation.15 This strategy allowed us to
identify a particular type of CNKCL, whose most striking
abnormal immunophenotypic feature consisted on lack or
dim CD56 expression. Our results indicate that CD56/dim
CNKCL accounts for an important proportion of all CNKCL
cases; despite this, cases of CD56/dim CNKCL have
been only sporadically described in the literature.10–14
Besides displaying abnormally low or even no CD56
expression, CD56/dim NK cells showed other immuno-
phenotypic differences with respect to normal blood
CD56 NK cells; they had a more homogeneous CD2
expression, an increased and more homogenous expres-
sion of CD11c and CD94, and an increased percentage
of HLA-DR and CD45RA/CD45RO cells, together with a
lower reactivity for CD7, CD11b, CD38, and CD45RA.23
Interestingly, once individually considered, most of these
features are also observed after NK cell activation However,
once the whole phenotypic pattern of CD56/dim NK cell is
taken into account (CD2ho, CD7/dim,ht, CD11cbright,ho,
CD57/dim, CD11b/dim,ht, CD94bright,ho, HLA-DR,ht) it
could never be detected in normal or activated/reactive NK
cells. Overall, these findings would indicate that the ex-
panded NK cell population is under the effect of some kind
of activation stimulus in vivo but it does not maturate nor-
mally. Such aberrant activation-related immunophenotype
was, in fact, the very first argument supporting the (mono-
)clonal nature of these neoplastic NK cells, which was sub-
sequently confirmed in a subset of female patients through
the HUMARA assay.
Although it is currently accepted that NK cells do not
rearrange the TCR genes, some cases of CNKCL with
clonal rearrangement of TCR- and/or TCR- genes have
been sporadically reported12,34 as also found here. The
1124 Lima et al
AJP October 2004, Vol. 165, No. 4
fact that concomitant clonal CD8 T-LGL and CNKCL
have also been described in the literature35 and that a
detailed molecular and phenotypic analysis of blood T
cells revealed T-cell abnormalities compatible with a
clonal T-cell proliferation in one of the three CD56/dim
CNKCL cases here described, indicates that the possi-
bility of co-existence of a monoclonal T-cell LGL prolifer-
ation and a CNKCL in a single patient should always be
considered. Except for reasons related to a common
origin of T and NK cells, no other reasonable explanation
can be found for the other two cases who revealed mono-
clonal TCR- and/or TCR- gene rearrangements; in fact,
the monoclonal rearrangement pattern was confirmed in
distinct assays although none of these patients showed
immunophenotypic evidence of a concomitant clonal T-
cell expansion.
The identification of those stimuli potentially responsi-
ble for the activation of CD56/dim NK cells remains a
challenge. Although we found evidence for a past infec-
tion with herpes viruses in most patients included in this
study, a high prevalence of past herpes virus infections
was also observed in controls. In agreement with previ-
ous studies,36,37 we did not find serological or molecular
evidence for EBV infection. The possibility of infection
with HHV-8, has also been ruled out in patients with T-cell
and NK cell LGL LPD.38
The fact that transgenic mice for the HTLV-I tax gene
develop NK cell LGL leukemia39,40 and that sera from
patients with both T-cell and NK cell LGL leukemia fre-
quently react with HTLV-I/II p21 envelope proteins41 had
lead to the hypothesis of a direct relationship between
CNKCL and infection by retroviruses. As in this series,
cases of HTLV42,43 or HIV-infected individuals44 associ-
ated with CNKCL have been previously described. How-
ever, efforts to document association of CNKCL and in-
fection with these45,46 or other retroviruses47 have been
also unsuccessful.
An alternative possibility to explain the failure in asso-
ciating CNKCL with any particular type of virus is that
infection by different viruses may play a role in the patho-
genesis of the disease by inducing a persistent NK cell
stimulation but that it may no longer be necessary in
sustaining the LGL proliferation. In line with this hypoth-
esis, and the results reported by Zambello and col-
leagues48 our findings provided serological/molecular
evidence for a viral infection in the large majority of pa-
tients with CD56/dim CNKCL.
Data presented here clearly shows that CD56/dim
CNKCL has an indolent clinical course and that most of
the clinical problems in patients with CD56/dim CNKCL
are related to the associated cytopenias, infections, and
neoplasias that are typically found in a great proportion of
cases. In contrast, organomegalies were rarely ob-
served, as did symptoms directly attributed to the LPD
itself. Despite this and the low tumor mass found in most
cases increased lactate dehydrogenase and 2-micro-
globulin levels were observed in most patients.
As in CD8 T-LGL, the exact mechanism by which
cytopenias associate to CD56/dim CNKCL is not
known. The possibility that a direct effect of BM infiltration
by leukemia cells is not likely, as cytopenias were usually
selective and their severity did not correlate with the
magnitude of the BM infiltration, which was mild in most
cases and only detected when careful cytological and
immunophenotypic studies were performed (data not
shown). The fact that Coomb’s direct-positive anemia has
been previously described in association with CNKCL49,50
and that increased levels of neutrophil and platelet-associ-
ated Igs were detected in some of our cases presenting
with neutropenia and thrombocytopenia, (data not shown)
may suggest an antibody-mediated immune mechanism.
Nevertheless, the true significance of these findings is not
known because only patients with cytopenias were tested
for the presence of these antibodies and they may be only
a consequence of the polyclonal hypergammaglobulinemia
associated with CNKCL;51 this was also probably the case
of the increased levels of other autoantibodies, observed in
some patients, without any apparent clinical significance. In
fact, clinical features that were previously reported in asso-
ciation to CD8 T-cell LGL leukemia, ie, arthritis, and
CNKCL, ie, fever of unknown origin and vasculitis, were only
sporadically found in patients with CD56/dim CNKCL.
The possibility of a direct cytotoxic effect of the ex-
panded CD56/dim NK cell population against normal
blood cells50 or a Fas/Fas-ligand mediated disturbance
of normal blood cells’ apoptosis52,53 should be further
investigated. In line with this hypothesis, one patient with
CNKCL and hemolytic anemia, whose NK cells displayed
cytotoxic activity against autologous erythrocytes has
been previously reported51 and anemia associated with
CNKCL usually responds to cyclosporine A.54,55 Irre-
spectively of the mechanism involved, it seems obvious
that cytopenias occur as a consequence of peripheral
destruction because they usually responded to cortico-
steroids and splenectomy and laboratorial evidence of
hemolysis was a frequent finding.
The mechanism that explains the high incidence of
neoplasias associated to CD56/dim NK cell is also
unclear. It could be speculated that the expanded
CD56/dim NK cell population are functionally abnormal
and unable to perform an adequate immune surveillance
against tumors. The marked deficiency found in the ex-
panded NK cells from our patients on the expression of
CD56 and CD11b, both of which are involved in adhesion
of NK cells to their targets, and target cell killing56–60
supports this hypothesis. Also in agreement with this
hypothesis is the fact that low levels of CD16 expression
were also observed in some cases. Nevertheless, the
overall amounts of TNF- and IFN- produced by NK
cells from normal PB and by CD56/dim NK cells in
patients with CNKCL were similar, although the latter
displayed a more heterogeneous response.
A major clinical concern in patients with CNKCL relates
to its potential transformation into a more aggressive
LPD. As previously described for CD8 and CD4 T-cell
LGL-leukemia, transformation of CNKCL into aggressive
NK cell malignancies may occur suggesting that both
T-cell and NK cell LGL-leukemia could be premalignant
conditions.61–65 In such cases, new chromosomal abnor-
malities are frequently detected suggesting that the ma-
lignant clinical behavior of the disease could probably
depend on additional oncogenic events.61,62 In line with
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these findings, one of our patients with longer follow-up had
evidence for disease progression with lung infiltration.
In summary our results would support the neoplastic
nature of expanded CD56/dim NK cells. Despite show-
ing an indolent clinical course CD56/dim CNKCL is
frequently associated with infections, cytopenias, and
neoplasias. Although the former may be involved in the
pathogenesis of the disease, the latter may translate the
existence of an altered immunosurveillance.
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